secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2024-09-27T23:59:59+00:00
Accession:  0001493152-24-038532
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics enters exclusive license with Factor Bioscience for cancer, autoimmune, rare disease tech
--------------------------------------------------------------------------------

- Exclusive license in cancer, autoimmune disorders, and rare diseases; replaces Nov 2023 and prior Exacis licenses.
- Pays Factor $208,333/month for first 12 months and $50,000/month for first 9 months for patent costs.
- Initial term one year, auto-renews; Eterna may terminate for any reason with 90 days notice.
- Factor to provide services and materials to facilitate development and scale-up at third-party facilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000149315224038532/0001493152-24-038532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000149315224038532/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-038532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer